Systemic sclerosis: Demographic, clinical and serological features in 100 Iranian patients

Rheumatology International

Volumn 33, Issue 8, 2013, Pages 1943-1950

  Poormoghim, Hadi ^a   Moghadam, Alireza Salek ^b   Moradi Lakeh, Maziar ^b   Jafarzadeh, Mehrzad ^b   Asadifar, Behnam ^b   Ghelman, Mohsen ^b   Andalib, Elham ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Auto antibodies; Disease subsets; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE;

ADULT; ARTHROPATHY; ARTICLE; CLINICAL FEATURE; FEMALE; FINGER ULCER; FOLLOW UP; GANGRENE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEP 2 CELL; HUMAN; IMMUNOFLUORESCENCE; IRAN; KIDNEY DISEASE; LUNG DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SEROLOGY; SKIN DISEASE; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; FEMALE; HUMANS; IRAN; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 84880916793     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2668-5     Document Type: Article

References (37)

1. Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev 7:588-593
2. Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35-42
3. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestation in systemic sclerosis: a report from the EULAR Scleroderma Trial and Research group database. Ann Rheum Dis 66:754-763
4. Meyer O (2006) Prognostic markers for systemic sclerosis. Joint Bone Spine 73:490-494
5. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9:R78. doi: 10.1186/ar2276
6. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and patogenesis. J Rheumatol 15:202-205
7. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Du Bountin LTH et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interestial lung disease. Arthritis Rheum 54:181-191
8. Medsger TA Jr, Steen VD (1996) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, MD, pp 51-64
9. Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al (2009) Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 1173:166-173
10. Hanke K, Dahnrich C, Bruckner C, Huscher D, Becker M, Janssen A et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11:R28
11. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelstssi C, La Montagna G et al (2002) Systemic sclerosis, demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 81:139-159
12. Mayes MD (2003) Scleroderma epidemiology. Rheum Dis Clin North Am 29:239-254
13. Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750-755
14. Solomon DH, Kavanaugh AJ, Schur PH (2002) The American College of Rheumatology Ad Hoc Committee on immunologic testing guidelines evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47:434-444
15. Hesselstrand R, Scheja A, Shen GO, Wiik A, Akesson AT (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 42:534-540
16. Vazquez-Abad D, Wallace S, Senecal JL, Joyal F, Roussin A, Earnshaw WC, Rothfield N (1994) Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 37:248-252
17. McNeilage LJ, Youngchaiyud U, Whittingham S (1989) Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 32(1):54-60
18. Steen DV, Powell LD, Medsger AT (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203
19. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA (1998) African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801-807
20. Bernstein RM, Steigerwald JC, Tan EM (1982) Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 48:43-51
21. Stupi AM, Steen VD, Owen GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension (PTH) in the CREST syndrome variant of progressive sclerosis (PSS). Arthritis Rheum 29:515-524
22. Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 40:1157-1162
23. Okano Y, Steen VD, Medsger ATA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrilliarin) in patients with systemic sclerosis. Arthritis Rheum 35:95-100
24. Primer G, Steen VD, Penning CA, Medsger T, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis. Arthritis Rheum 31:525
25. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75-83
26. Harvey G, Black C, Maddison P, McHugh N (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24:477-484
27. Chang M, Wang R, Yangco D, Sharp G, Komatireddy G, Hoffman R (1998) Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopath 89:71-78
28. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T et al (2009) Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunoassay. Rheumatology 48:1570-1574
29. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA polymerase and other autoantibody specification in systemic sclerosis. Br J Rheumatol 37:15-20
30. Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005-1013
31. Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP (2009) A longitudinal study of anti-RNA polymerase III antibody level in systemic sclerosis. Rheumatology 48:1218-1221
32. Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403-413
33. Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14(1):111-124
34. Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S et al (1999) Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 117:383-387
35. Reveille JD, Solomon DH (2003) American College of Rheumatology, Ad Hoc Committee on immunological testing guidelines evidence-based guidelines for the use of immunologic laboratory tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 15(49):399-412
36. Dick T, Mierau R, Bartz-Bazzanaella P (2002) Coexistence of antitopoisomeras and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61:121-127
37. Kuwana M, Kimura K, Hirakata M (2002) Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61:842-846